The purpose of the study is to evaluate how well lutikizumab works in reducing the symptoms of ulcerative colitis and to monitor any side effects. The study will involve both intravenous (IV) and subcutaneous (SC) forms of lutikizumab, meaning the medication will be administered either through a vein or under the skin. Participants will be monitored over a period of time to assess changes in their disease activity and any adverse events they may experience.

Throughout the study, participants will undergo regular assessments to track their progress. The study aims to determine the percentage of participants who show improvement in their condition by week 12. This includes looking at endoscopic improvement, which involves examining the inside of the colon, as well as clinical remission and response, which refer to the reduction or disappearance of symptoms. The study is expected to last for up to 52 weeks, providing valuable information on the long-term effects of lutikizumab in treating ulcerative colitis.

The purpose of the study is to see if the combination of BI 690517 and empagliflozin is more effective than empagliflozin alone in helping people with heart failure. Participants in the study will be randomly assigned to receive either the combination of BI 690517 and empagliflozin or a placebo and empagliflozin. The study will last for a period of 42 days, during which participants will take the medications orally, meaning they will swallow them in the form of tablets.

Throughout the study, researchers will monitor participants to see how the treatment affects their heart failure symptoms and overall health. The main focus will be on the time it takes for a participant to experience a serious heart-related event, such as a heart-related death or hospitalization due to heart failure. The study aims to provide valuable information on whether the new combination treatment can improve outcomes for people living with heart failure.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

The purpose of this study is to evaluate the long-term safety of ABX464 in individuals who have previously participated in related studies. Participants will continue taking the medication over an extended period, and their health will be monitored to assess any side effects and the overall effectiveness of the treatment. The study aims to gather information on how well patients respond to the medication over time, including any improvements in their symptoms and overall health.

Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their health. This includes looking at specific markers in the blood and stool that indicate inflammation, as well as using imaging techniques to assess the heart’s function. The study will also track any adverse events or side effects experienced by participants to ensure the medication’s safety. The information collected will help determine the potential benefits and risks of using ABX464 for treating moderate to severe ulcerative colitis.